Synalar 10/Synalar 25/Synalar HP Special Precautions

Prolonged use of topical corticosteroid products may produce atrophy of the skin. When used on the face, this may occur even with short term use.
Significant systemic absorption may result when corticosteroids are applied over a large areas of the body, even when occlusion is not used.
This preparation is not for ophthalmic use.
In the presence of an infection, the use of an appropriate antibacterial, antiviral or antifungal agent should be instituted. If a favourable response does not occur promptly, Fluocinolone acetonide (Synalar 10/Synalar 25/Synalar HP) should be discontinued until the infection has been adequately controlled.
Use in Children: Administration of topical corticosteroids to children should be limited to a short period of time and to the smallest amount compatible with an effective therapeutic regimen.
Synalar 10/Synalar 25: Topical corticosteroids should be used with caution on lesions close to the eye.
When used with occlusive dressing, the lesions should be carefully inspected between dressings to determine whether infection is developing. On infrequent occasions, miliaria, folliculitis, or pyodermas have been seen with the use of this technique. The development of infection requires appropriate local or systemic antibacterial therapy and discontinued of the occlusive dressing method.
Use in Pregnancy & Lactation: See Use in Pregnancy & Lactation section for further information.
Synalar HP: Fluocinolone acetonide (Synalar HP) 2 mg/g (0.2% w/w) Cream should not be used for prolonged periods and the quantity per day should not exceed 2 g of formulated material.
If no response is observed during the first week of therapy, medication should be discontinued. However, if a response is noted, therapy may continue for a maximum of three weeks. It is recommended that Synalar 0.025% or 0.01% concentrations be utilized for maintenance therapy beyond this period of time.
Occlusive dressing increases the percutaneous absorption of topical corticosteroids. Its use can be helpful in the treatment of recalcitrant dermatoses. Tight-fitting diapers or plastic pants on a child may also function as an occlusive dressing and increase absorption of topical corticosteroids by the underlying skin.
Patients (particularly children) receiving a large dose of topical corticosteroid applied to a large surface area or under an occlusive dressing should be evaluated for evidence of hypothalamic-pituitary-adrenal (HPA) axis suppression. If HPA axis suppression is noted, the dose should be reduced or the corticosteroid discontinued.
Use in Children: Fluocinolone acetonide (Synalar HP) 2 mg/g (0.2% w/w) Cream should not be used on infants up to two years of age.